



Global

Search

[Media](#) | [Investors](#) | [Consumers](#) | [Healthcare professionals](#) | [Business to business](#) | [Partnerships](#)
[Contact us](#)[Home](#) [About us](#) [Products](#) [Careers](#) [Our stories](#) [Research](#) [Responsibility](#)

Media

[GSK/Novartis transaction](#)[Press releases](#)[Media contact details](#)[Social media](#)[Resource centre](#)[Image and video library](#)[Home](#) > [Media](#) > [Press releases](#) >[GSK China Investigation Outcome](#)

GSK China Investigation Outcome

19 September 2014

GlaxoSmithKline plc (GSK) today announced that the Changsha Intermediate People's Court in Hunan Province, China ruled that GSK China Investment Co. Ltd (GSKCI) has, according to Chinese law, offered money or property to non-government personnel in order to obtain improper commercial gains, and been found guilty of bribing non-government personnel. The verdict follows investigations initiated by China's Ministry of Public Security in June 2013.

As a result of the Court's verdict, GSKCI will pay a fine of £297 million (3 billion RMB at a currency exchange rate of 10.0980) to the Chinese government. This will be funded through existing cash resources. Associated costs and charges related to restructuring will be included in GSK's third quarter update.

The illegal activities of GSKCI are a clear breach of GSK's governance and compliance procedures; and are wholly contrary to the values and standards expected from GSK employees. GSK has published a statement of apology to the Chinese government and its people on its website (www.gsk-china.com).

GSK uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our [cookie policy](#)

[Agree](#) [Disagree](#)

GSK Chief Executive Officer, Sir Andrew Witty said:
"Reaching a conclusion in the investigation of our Chinese business is important, but this has been a deeply disappointing matter for GSK. We have and will continue to learn from this. GSK has been in China for close to a hundred years and we remain fully committed to the country and its people. We will continue to expand access to innovative medicines and vaccines to improve their health and well-being. We will also continue to invest directly in the country to support the government's health care reform agenda and long-term plans for economic growth."

GSK – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.

[Sitemap](#)

[Terms of use](#)

[Accessibility](#)

[Cookie policy](#)

[Privacy](#)

[GSK employees](#)

© 2001-2014 GlaxoSmithKline plc. All rights reserved. Registered in England and Wales No. 3888792.

Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.

